Vermillion targets $31.5M from funding round

05/10/2013 | GenomeWeb Daily News (free registration)

Austin, Texas-based molecular diagnostics firm Vermillion hopes to raise as much as $31.5 million through the sale of 8 million shares of stock. Part of the proceeds will go toward improving sales and reimbursements for the company's OVA1 assay, which is used to distinguish malignant from benign ovarian tumors.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC